Get the Stockscreener App
4.14
0.96%
-0.04
After Hours:
4.13
-0.010
-0.24%
Cingulate Inc Stock (CING) Latest News
Cingulate (NASDAQ:CING) Trading Down 2.1% – Here’s Why - Defense World
Cingulate stock price target raised to $20 at H.C. Wainwright - MSN
Cingulate CEO cleared of charges, retains board confidence - Investing.com India
Cingulate CEO cleared of charges, retains board confidence By Investing.com - Investing.com Australia
Q4 Earnings Forecast for Cingulate Issued By HC Wainwright - Defense World
Cingulate (NASDAQ:CING) Price Target Raised to $20.00 - Defense World
Cingulate Inc. adjusts executive compensation - MSN
Brokers Issue Forecasts for Cingulate FY2025 Earnings - Defense World
Cingulate stock price target raised to $20 at H.C. Wainwright By Investing.com - Investing.com Nigeria
Meta Platforms To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Public company CEO concludes case alleging aggravated domestic battery - The Business Journals
Cingulate Inc. adjusts executive compensation By Investing.com - Investing.com Australia
Jane Street Group LLC Invests $106,000 in Cingulate Inc. (NASDAQ:CING) - Defense World
Cingulate stock rated Buy by Roth/MKM, anticipates $1.6B sales potential - Investing.com Canada
Cingulate (NASDAQ:CING) Coverage Initiated at Roth Mkm - Defense World
Roth Capital Upgrades Cingulate (NASDAQ:CING) to “Strong-Buy” - Defense World
Roth MKM Initiates Coverage of Cingulate (CING) with Buy Recommendation - MSN
CINGWCingulate Inc. Warrants Latest Stock News & Market Updates - StockTitan
Cingulate Inc Completes Key FDA Study for ADHD Drug - TipRanks
Final Study Completed for Cingulate’s Lead Asset CTx-1301 - GlobeNewswire
Cingulate Completes Final FDA Study for Once-Daily ADHD Drug CTx-1301 with Zero Safety Issues - StockTitan
Cingulate Inc. Enters into Note Purchase Agreement with Streeterville Capital, LLC - Defense World
Cingulate secures capital ahead of 2025 plans to submit drug for FDA approval - The Business Journals
Cingulate Inc Secures $5M Financing for Strategic Growth - Yahoo Finance
Cingulate Inc. announced that it has received $5 million in funding - Marketscreener.com
Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000 - GlobeNewswire
Cingulate Secures $5M Financing Deal to Advance CTx-1301 Drug Development Through 2025 - StockTitan
Cingulate (NASDAQ:CING) Upgraded at Maxim Group - Defense World
U.S. Stock market top gainers: Binah Capital Group gains +107.02%, Aligos Therapeutics surges by 42.84% in mid day trading - Business Upturn
Cingulate Inc. Announces Third Quarter Financial Results and Clinical Update - Defense World
Cingulate Inc (CING) Quarterly 10-Q Report - Quartz
CINGCingulate Inc. Latest Stock News & Market Updates - StockTitan
Cingulate reports Q3 net loss $3.2M vs. $5.98M last year - TipRanks
Cingulate Reports Third Quarter 2024 Financial - GlobeNewswire
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market - StockTitan
Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show - The Manila Times
Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show - GlobeNewswire
Cingulate secures funding to extend operations into Q2 2025 By Investing.com - Investing.com South Africa
SEC Form 424B3 filed by Cingulate Inc. - Quantisnow
Cingulate secures funding to extend operations into Q2 2025 - Investing.com India
Cingulate Inc Files for 1.5M Share Offering by Selling Stockholders - Investing.com Canada
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):